Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines
Autor: | Renata Veselská, Markéta Hermanová, Jaroslav Sterba, Tomáš Loja, Karel Zitterbart, Karel Vesely, Iva Staniczková Zambo, Petr Chlapek |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2008 |
Předmět: |
Adult
Male Cancer Research Pathology medicine.medical_specialty Adolescent Fluorescent Antibody Technique Nerve Tissue Proteins macromolecular substances Biology lcsh:RC254-282 Nestin 03 medical and health sciences 0302 clinical medicine Intermediate Filament Proteins Cancer stem cell Antigens CD Cell Line Tumor Genetics medicine Intermediate Filament Protein Humans Neoplastic transformation AC133 Antigen Progenitor cell Intermediate filament Child 030304 developmental biology Glycoproteins 0303 health sciences Osteosarcoma Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Immunohistochemistry Oncology nervous system Cell culture 030220 oncology & carcinogenesis embryonic structures Cancer research Neoplastic Stem Cells Female Stem cell Peptides Research Article |
Zdroj: | BMC Cancer BMC Cancer, Vol 8, Iss 1, p 300 (2008) |
ISSN: | 1471-2407 |
Popis: | Background Nestin was originally identified as a class VI intermediate filament protein that is expressed in stem cells and progenitor cells in the mammalian CNS during development. This protein is replaced in the adult organism by other intermediate filament proteins; however, nestin may be re-expressed under certain pathological conditions such as ischemia, inflammation, brain injury, and neoplastic transformation. Nestin has been detected in many kinds of tumors, especially in tumors derived from the CNS. Co-expression of nestin and the CD133 surface molecule is considered to be a marker for cancer stem cells in neurogenic tumors. Our work was aimed at a detailed study of nestin expression in osteosarcomas and osteosarcoma-derived cell lines. Methods Using immunodetection methods, we examined nestin in tumor tissue samples from 18 patients with osteosarcomas. We also successfully established permanent cell lines from the tumor tissue of 4 patients and immunodetection of nestin and CD133 was performed on these cell lines. Results Nestin-positive tumor cells were immunohistochemically detected in all of the examined osteosarcomas, but the proportion of these cells that were positively stained as well as the intensity of staining varied. Nestin-positive cells were rarely observed in 2 tumor samples, and the remaining 16 tumor samples showed various nestin expression patterns ranging from very sporadic occurrence to an overwhelming proportion of cells with strong positive staining. Three of the established osteosarcoma cell lines were demonstrated to be nestin-positive, and only one cell line showed no expression of nestin; this finding corresponds with the rare occurrence of nestin-positive cells in the respective tumor sample. Moreover, three of these osteosarcoma cell lines were undoubtedly proven to be Nes+/CD133+. Conclusion Our results represent the first evidence of nestin expression in osteosarcomas and suggest the possible occurrence of cells with a stem-like phenotype in these tumors. |
Databáze: | OpenAIRE |
Externí odkaz: |